Search

Search Constraints

You searched for: Author/Creator Mueller, Andre

Search Results

1. [IC‐01–05]: FIRST‐IN‐HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18‐F PI‐2620 IN ALZHEIMER's DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLS. (1st July 2017)

2. [IC‐P‐192]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES. (1st July 2017)

3. [P2–381]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES. (1st July 2017)

4. Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. Issue 11 (November 2021)

5. First‐in‐human [18F]D2‐Deprenyl‐PET imaging and GFAP evaluation as biomarkers of reactive astrogliosis in neurodegenerative diseases. (20th December 2022)

6. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study. Issue 8 (27th March 2015)

7. IC‐P‐040: EVALUATION OF TAU DEPOSITION IN AMYLOID POSITIVE MCI OR MILD‐AD DEMENTIA SUBJECTS FROM THE ELENBECESTAT MISSION AD PROGRAM USING [18 F]PI‐2620 PET. (1st July 2019)

8. IC‐P‐220: CLINICAL UPDATE: 18F‐PI‐2620, A NEXT GENERATION TAU PET AGENT EVALUATED IN SUBJECTS WITH ALZHEIMER'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY. (1st July 2006)

9. In Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer's Disease. (20th December 2022)

10. In Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer's Disease. (20th December 2022)